share_log

Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report

Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report

丹纳赫表示有兴趣收购价值可观的Catalent：报告
Benzinga Real-time News ·  2023/02/06 07:47
  • Danaher Corporation (NYSE:DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE:CTLT).
  • According to the sources, the recent moves by the life science firm valued Catalent at a significant premium.
  • It's unclear how Catalent will proceed or whether it's receptive to a takeover offer, Bloomberg reported citing people familiar with the matter.
  • Related: Danaher Says 2022 'Another Great Year,' Delivers Around 10% Core Revenue Growth.
  • Danaher and Catalent deal could be one of the largest transactions this year in a sleepy dealmaking market, with volumes down two-thirds globally, the report added.
  • "As a matter of company policy, Catalent does not comment on market rumors or speculation," the report cited a company spokesperson.
  • Also Read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.
  • Last year, Catalent received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE:NVO) obesity drug Wegovy.
  • Catalent provides delivery technologies and development solutions for drugs, biologics, and consumer health products. The manufacturer has gained distinction during the pandemic, helping to produce COVID-19 vaccines and treatments in partnership with companies including Moderna Inc (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and AstraZeneca Plc (NASDAQ:AZN).
  • Price Action: CTLT shares are up 25.74% at $70.48 during the premarket session on the last check Monday.
  • 丹纳赫公司 据报道，纽约证券交易所代码：DHR）已表示有兴趣收购合同制造商 Catalent Inc （纽约证券交易所代码：CTLT）。
  • 据消息人士透露，这家生命科学公司最近的举措对Catalent的估值高得多。
  • 彭博社援引知情人士的话报道，目前尚不清楚Catalent将如何发展，也不清楚它是否愿意接受收购要约。
  • 相关： 丹纳赫说 2022 年 “又是美好的一年”，核心收入增长了约 10%。
  • 报告补充说，丹纳赫和卡塔伦特的交易可能是今年在昏昏欲睡的交易市场中最大的交易之一，全球交易量下降了三分之二。
  • 报告援引公司发言人的话说：“就公司政策而言，Catalent不对市场传闻或猜测发表评论。”
  • 另请阅读： 这位分析师说，Catalent-Repligen合并 “似乎不太可能”。
  • 去年，Catalent收到了美国食品药品管理局关于其比利时注射器灌装设施的文章，“据称” 是比利时供应短缺的罪魁祸首 Novo Nordisk A/S （纽约证券交易所代码：NVO）肥胖药物 Wegovy。
  • Catalent 为药物、生物制剂和消费者健康产品提供交付技术和开发解决方案。该制造商在疫情期间赢得了声誉，与包括以下在内的公司合作帮助生产 COVID-19 疫苗和治疗方法 Moderna Inc （纳斯达克股票代码：MRNA）， 强生公司 （纽约证券交易所代码：JNJ），以及 阿斯利康有限公司 （纳斯达克股票代码：AZN）。
  • 价格走势： 在周一的最后一次盘前交易中，CTLT股价上涨了25.74％，至70.48美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发